Results 111 to 120 of about 282,112 (262)

Single‐Cell RNA Sequencing of Peripheral Blood Defines Two Immunologic Subtypes of Sjögren's Disease Distinguished by Anti‐SSA Antibodies and Aberrant B Cell Populations

Arthritis &Rheumatology, EarlyView.
Objective Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski, Kimberly E. Taylor, Emily Flynn, Armita Norouzi, Catherine Chu, Brittany Davidson, Arnab Ghosh, Joanne Nititham, Ravi K. Patel, Annie W. Poon, Gabriela K. Fragiadakis, Alexis J. Combes, Walter L. Eckalbar, Lindsey A. Criswell, Chun Jimmie Ye, Caroline H. Shiboski   +15 more
wiley   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source

Early Diagnosis of Axial Spondyloarthritis Is Associated With Less Long‐Term Spinal Structural Damage: A Longitudinal Analysis of the Swiss Clinical Quality Management in Rheumatic Diseases Registry

Arthritis &Rheumatology, EarlyView.
Objective The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration of two years or less of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between patients with early and established axSpA treated with biologic/targeted synthetic disease ...
Annik Steimer, Jonas Brändli, Mauro Bachmann, Andrea Götschi, Claudia L. Rodrigues, Michael J. Nissen, Burkhard Möller, Kristina Bürki, Martin Wendiggensen, Simon Grosswiler, Michael Andor, Diana Dan, Frauke Förger, Sabine Adler, Diego Kyburz, Oliver Distler, Raphael Micheroli, Sofia Ramiro, Adrian Ciurea   +18 more
wiley   +1 more source

HLA Typing [PDF]

, 2020
openaire   +1 more source

Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Graphical Abstract Objective This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. Methods Whole blood RNA sequencing was performed
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C. Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

The Association Between Systemic Inflammation as Measured by Calprotectin and Autoantibody Load in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Plasma calprotectin is a marker of neutrophil activity. Its relation to the clinical phenotype and autoantibodies in rheumatoid arthritis (RA) is only partly understood. We therefore aimed to investigate the association between calprotectin and the clinical parameters C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti–cyclic
Caroline Grönwall, Linda Mathsson Alm, Helga Westerlind, Isabel Gehring, Nasim Ghasemzadeh, Niels Steen Krogh, Siri Lillegraven, Espen Haavardsholm, Martina Johannesson, Tore K. Kvien, Johan Rönnelid, Tue Wenzel Kragstrup, Bente Glintborg, Merete Lund Hetland, Hilde Berner Hammer, Danish Rheumatologic Biobank Study Group, Swedish Rheumatology Quality Register Biobank Study Group, Oliver Hendricks, Estrid Høgdall, Dorte Vendelbo Jensen, Heidi Lausten Munk, Jens Kristian Pedersen, Torkell Ellingsen, Anne Gitte Loft, Ellen‐Margrethe Hauge, Salome Kristensen, Lene Dreyer, Asta Linauskas, Søren Jacobsen, Carl Turesson, Solbritt Rantapää Dahlqvist, Lena Björkman, Alf Kastbom, Eva Baecklund, Johan Askling   +34 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source

Identification of the Novel HLA-DQB1*06:432 Allele by Sequence-Based Typing

HLA-DQB1*06:432 differs from HLA-DQB1*06:09:01:01 by a nonsynonymous nucleotide substitution in codon 186, changing Valine to ...
John Jeongseok Yang, Heung-Bum Oh
core   +1 more source